Bone Biologics Corp · NASDAQ:BBLG
Bone Biologics — Investor Presentation (January 2022)
19 slides from Bone Biologics's investor presentation, January 2022
Slide 1: Regenerative Medicine for Bone
Regenerative Medicine for Bone January 2022 Confidential & Proprietary 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains “forward-looking” statements, including, without limitation, statements relating to: the future of Bone Biologics; our business strategy and plans; the ongoing development of our product candidates; our plans to commercialize, and the market potential
Slide 3: Bone Biologics is redefining bone regeneration with NELL-1
Bone Biologics is redefining bone regeneration with NELL-1, a growth factor that has already demonstrated an increase in the quantity and quality of bone in large animal models, while displaying a strong safety profile
Slide 4: Thesis: A disruptive technology in clinical development
Thesis A disruptive technology in clinical development 1 Confidential & Proprietary 4
Slide 5: Large Addressable Orthobiologics Market
Large Addressable Orthobiologics Market $3 Billion Global Bone Graft Substitute Market Sources: Orthopedic Confidential Network & Proprietary 5 News
Slide 6: Bone Biologic's Solution
Bone Biologic’s Solution Hard Healer Fusion remains a critical clinical unmet need A major challenge in orthopedic surgery is effective bone regeneration – especially in hard healers Challenges w/ Proposed Nell-1 rhBMPs Solution Rapid, uncontrolled Rapid, controlled, guided bone growth can cause
Slide 7: Nell-1 Product Pipeline
Nell-1 Product Pipeline Focus on fusion provides a differentiated product in clinical need Clinical Discovery Pre-Clinical Pilot Pivotal Indication` Spine Fusion Trauma Osteoporosi s Confidential & Proprietary 7
Slide 8: NELL-1 Mechanism of Action
NELL-1 Mechanism of Action Improved safety from later pathway interaction Differentiates To bone BONE FORMATION Pre- Osteobla osteoblast st Cell Cell Runx Mesenchy 2 mal Stem NELL-1 Cells --- -- rhBM P NELL-1 acts later in the pathway of bone formation and only grows bone in presence of bone (impr
Slide 9: Surgical Procedure Remains the Same
Surgical Procedure Remains the Same No change to protocol with orthobiologic prep and implantation 1 -- NELL-1 + DBX inserted into PEEK cage 2 -- Implantation site in the spine 3 -- Implanted cage 4 -- Posterior pedicle screw fixation Confidential & Proprietary 9
Slide 10: Nell-1 Product Kit
Nell-1 Product Kit Easy-to-administer kit for commercial distribution Recombinant NELL-1 is purified and mixed with 510- 1 K-cleared Demineralized Bone Matrix putty in the operating room. rhNELL-1 DBM A vial of NELL-1/DBM will be sold in a convenience kit with a diluent and a syringe of demineralize
Slide 11: Studies demonstrate safety and effectiveness
Studies demonstrate safety and effectiveness • Spine fusion effectiveness demonstrated across 3 animal species (rodent, sheep, NHP) • Extensive outcome measures including micro CT, x-ray, histology, and biomechanics • Completed two clinically relevant sheep studies that demonstrated that rhNELL-1 in
Slide 12: Clinical Strategy
Clinical Strategy A well-established pathway to success FDA acceptance to use pilot study data in Australia to enable US pivotal study Human Research Ethics Committee (HREC) approval for First in Man study in Australia 30 subjects: 12= 2.0mg/mL; 12=1.5 mg/mL; 6=local autograft TLIF, single-lev
Slide 13: Strong IP Barrier
Strong IP Barrier Exclusive license to NELL-1 technology from UCLA for spine, trauma, and osteoporosis 13 issued patents with more than 200 claims IP strategy is to expand portfolio via composition of matter, methods of use and methods of production Patent No. Title Issued U.S. Patent No. 9,511,1
Slide 14: Over 45 Peer Reviewed Publications
Over 45 Peer Reviewed Publications Nell-1 demonstrates technology viability Bone Biologics has accumulated a deep collection of publications on NELL-1; a significant amount of work has been undertaken to support a potential solution for hard healers. 14 Confidential & Proprietary
Slide 15: Management Team
Management Team Jeffrey Frelick, CEO and President COO Life Science Enterprises 15 yrs. Med-Tech analyst, Canaccord, ThinkEquity, Lazard, Leerink Consultant, Boston Biomedical Consultants Regional Sales Mgr., Becton Dickinson PCD Laboratory Technologist, Clinical Pathology Facility Deina W
Slide 16: Board of Directors
Board of Directors Steve La Neve Don Hankey Executive VP, International at Globus Medical Chairman of the Board Bone Biologics / CEO Hankey Mr. La Neve brings 35 years of health care experience and Group leadership to Bone Biologics. Previously Mr. La Neve was CEO Mr. Hankey holds his BA and post-gr
Slide 17: Achievements
Achievements A clear pathway to approval Capital raise NASDAQ ISO 10993 uplist testing Initiate Pivotal Study FDA Analyst Dev. In Vitro Approval coverage assay Engineering Finalize carrier run Pilot study Submit PMA supply agreement 12 mos. data Application Initiate Pilot Study Fuji Diosynth agreeme
Slide 18: Summary
Summary 1 Confidential & Proprietary 18
Slide 19: www.bonebiologic s.com NASDAQ:
1 www.bonebiologic NASDAQ: s.com Confidential & Proprietary BBLG 19
Bone Biologics — Investor Presentation (January 2022) on 6ix